Ovid Therapeutics
OVID
50 hedge funds and large institutions have $21.7M invested in Ovid Therapeutics in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 6 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
31% more capital invested
Capital invested by funds: $16.5M → $21.7M (+$5.2M)
6% more funds holding
Funds holding: 47 → 50 (+3)
4.03% more ownership
Funds ownership: 27.73% → 31.77% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$8.24M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$905K |
| 4 |
Renaissance Technologies
New York
|
+$771K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$768K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.87M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$191K |
| 3 |
JP Morgan Chase
New York
|
-$101K |
| 4 |
Millennium Management
New York
|
-$54K |
| 5 |
SG Americas Securities
New York
|
-$46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Millennium Management
New York
| – | -$54K | -22,286 | Closed |
|
|
52
SG Americas Securities
New York
| – | -$46K | -18,870 | Closed |
|
|
PPA
53
Parametric Portfolio Associates
Seattle,
Washington
| – | -$26K | -10,580 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$24K | -10,101 | Closed |
|
55
Russell Investments Group
London,
United Kingdom
| – | -$1K | -500 | Closed |
|
56
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$455 | -182 | -97% |
|
OVID Hedge Fund Activity: Q1 2019 in Review
50 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2019, worth a combined $21.7M — up 31% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OVID positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $8.24M. The largest seller was BlackRock, cutting an estimated $1.87M.
- 50 institutional investors held Ovid Therapeutics (OVID) as of Q1 2019, up from 47 in Q4 2018.
- Funds reported $21.7M of Ovid Therapeutics stock for Q1 2019, up 31% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q1 2019 and 6 closed out, a net change of +3 holders.
- The largest Ovid Therapeutics buyer in Q1 2019 was BVF Inc, an estimated $8.24M added.
- The largest Ovid Therapeutics seller in Q1 2019 was BlackRock, an estimated $1.87M sold.
Based on aggregated 13F filings for Q1 2019.